Lilly buys Adverum for its phase 3-stage eye disease gene therapy
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Subscribe To Our Newsletter & Stay Updated